» Articles » PMID: 26857504

Humoral Cross Reactivity Between α-synuclein and Herpes Simplex-1 Epitope in Parkinson's Disease, a Triggering Role in the Disease?

Overview
Journal J Neuroimmunol
Specialty Neurology
Date 2016 Feb 10
PMID 26857504
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Environmental factors are implicated in the development of Parkinson's disease (PD). We have investigated on the role of molecular mimicry between HSV1 and α-synuclein that could foster the progression of PD. The antibody response against homologous peptides in PD patients and healthy controls was evaluated, showing that these antibodies are highly prevalent among PD patients to healthy controls. The competitive assay demonstrated cross-reactivity between HSV1 and human α-synuclein peptides. The results may suggest the hypothesis of the involvement of HSV1 in stimulating the immune cells against the neurons of the substantia nigra as a consequence of the cross reactivity.

Citing Articles

Association between herpes zoster and Parkinson's disease and dementia: a systematic review and meta-analysis.

Zhang Y, Liu W, Xu Y Front Neurol. 2024; 15:1471736.

PMID: 39703359 PMC: 11655326. DOI: 10.3389/fneur.2024.1471736.


Parkinson's Disease and the Microbiota-Gut-Brain Axis: Metabolites, Mechanisms, and Innovative Therapeutic Strategies Targeting the Gut Microbiota.

Ran Z, Mu B, Wang D, Xin-Huang , Ma Q, Lu M Mol Neurobiol. 2024; 62(4):5273-5296.

PMID: 39531191 DOI: 10.1007/s12035-024-04584-9.


Systemic immune challenge exacerbates neurodegeneration in a model of neurological lysosomal disease.

Mandolfo O, Parker H, Aguado E, Learmonth Y, Liao A, OLeary C EMBO Mol Med. 2024; 16(7):1579-1602.

PMID: 38890537 PMC: 11251277. DOI: 10.1038/s44321-024-00092-4.


Use of antiviral drugs and incidence of Parkinson's disease in Taiwan.

Zhang H, Xie J, Peng H, Lin Y, Song J PLoS One. 2024; 19(5):e0302383.

PMID: 38713724 PMC: 11075903. DOI: 10.1371/journal.pone.0302383.


Environmental risk factors provoke new thinking for prevention and treatment of dementia with Lewy bodies.

An D, Xu Y Heliyon. 2024; 10(9):e30175.

PMID: 38707435 PMC: 11068646. DOI: 10.1016/j.heliyon.2024.e30175.